LOS ANGELES, CA / ACCESSWIRE / May 19, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE MKT: TXMD) concerning possible violations of federal securities laws between July 7, 2016 and April 9, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired the Company's shares during the Class Period, should contact the firm prior to the June 19, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at email@example.com.
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also do nothing and be an absent class member.
According to the Complaint, through the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that the Company's New Drug Application ("NDA") submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the U.S. Food & Drug Administration's potential approval of the NDA. Upon release of this information, the Company's stock price declined materially, which harmed investors according to the Complaint.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Lundin Law PC
Brian Lundin, Esq.
SOURCE: Lundin Law PC